Objective: To explore the molecular mechanism by which cordycepin inhibits cell proliferation and induces apoptosis of human colorectal cancer cells. Methods: Cell counting and MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfopheny)-2H-tetrazolium, inner salt) method were used to monitor the effects of cordycepin on cell proliferation. Flow cytometry (FCM) was used to analyze the effects of cordycepin on the cell cycle progress. Annexin V-fluorescein isothiocyanate (FITC) analysis was used to detect apoptosis at a very early stage. Caspase-Glo was used to determine caspase activity and Western blot was used to measure protein expression levels of c-Jun N-terminal kinase (JNK), p38, and Bcl-2 pro-apoptosis family. Results: The numbers of viable SW480 and SW620 cells and the proliferation of these cells were significantly reduced with increases in cordycepin concentration (P<0.01). The cell cycle progression of SW480 and SW620 was arrested at the G0/G1 phase by the addition of cordycepin, and apoptosis rates of cordycepin treatments were increased compared with the control group. Cordycepin-treated cells showed phosphatidylserine valgus, suggesting the existence of early apoptosis. Caspase-3/7 and -9 activity significantly increased and the protein expression levels of JNK, p38, and Bax, Bid, Bim, and Puma from Bcl-2 pro-apoptosis molecules also increased after the treatment with cordycepin. Conclusions: Cordycepin can inhibit SW480 and SW620 cell proliferation and induce apoptosis. Apoptosis might be induced by enhancing JNK and p38 kinase activity and increasing the protein expression of Bcl-2 pro-apoptotic molecules.
Introduction
Cordyceps sinensis is a rare herb traditionally used in Chinese medicine. It has been widely used in China for anti-aging and nourishing, and has been used for the treatment of various diseases such as cancer, hypertension, hepatitis, hyperglycemia, and hypercholesterolemia. It has also been reported to possess anti-tumor properties as well as the ability to scavenge free radicals and stimulate immunity (Lo et al., 2004; Wang et al., 2005; Wu et al., 2007; Paterson, 2008) . Cordycepin (3-deoxyadenosine, 3'-dA) is the main active ingredient. Early studies have shown that cordycepin has various biological activities, which include inhibiting inflammation (Kim et al., 2006) , inhibiting platelet aggregation (Cho et al., 2007) , strengthening the immune system (Zhou et al., 2008) , inhibiting the polyadenylation of mRNA (Lallas et al., 2004) , and inhibiting human immunodeficiency virus infection (Müller et al., 1991) . Studies also have shown that cordycepin has significant anti-tumor effects such as inhibiting cell proliferation and metastasis (Nakamura et al., 2005; Chang et al., 2008; Shi et al., 2008) , inducing apoptosis (Wehbe-Janek et al., 2007; Wu et al., 2007; Thomadaki et al., 2008) , and interfering with cell signaling pathways (Lee et al., 2009; Wong et al., 2010) . Cordycepin is one of the 18 new anti-cancer drugs currently being investigated and developed by the National Cancer Institute in the USA (Kodama et al., 2000) . However, the molecular mechanism by which cordycepin inhibits tumor cell proliferation and induces apoptosis remains unclear.
Proteins in the Bcl-2 family are key regulators involved in cell apoptosis. The Bcl-2 family includes anti-apoptotic and pro-apoptotic members which regulate the stabilities of mitochondrial structure and function. In other words, they act as "on/off switches" of the apoptosis pathway at the mitochondrial level (Cory et al., 2003; Willis and Adams, 2005) . The growth factor receptor-mediated mitogen-activated protein kinase (MAPK) signal transduction pathway has been found to be activated at the occurrence of colorectal cancer, and it is also closely related to cell proliferation and differentiation (Schwartsmann et al., 2005; Roberts and Der, 2007) . Three MAPK pathways have been found so far: the extracellular signalregulated protein kinase (ERK) pathway, c-Jun N-terminal kinase (JNK) pathway, and p38 MAPK pathway. However, since it has not been proven that cordycepin affected Bcl-2 family expression and activation of MAPK pathways, further study is needed.
This study analyzed the effects of cordycepin on colorectal cancer cell proliferation and apoptosis, and also studied the relationship between caspase and the Bcl-2 family.
Materials and methods

Main reagents
Leibovitz L-15 culture medium and trypsin were purchased from Gibco Inc., USA. Phosphate buffered saline (PBS), dimethylsulfoxide (DMSO), trypan blue dye, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfopheny)-2H-tetrazolium inner salt (MTS), and fetal bovine serum (FBS) were purchased from Hangzhou Sijiqing Biological Engineering Materials Co., Ltd., Hangzhou, Zhejiang, China. Propidium iodide (PI) was purchased from Sigma Chemical Co., USA. Annexin V apoptosis detection kit and monoclonal antibodies for Bcl-2 pro-apoptotic family and the MAPK family were purchased from the Cell Signaling Inc., USA. Caspase-Glo ratio colorimetric analysis kit was purchased from Promega Co., USA. Cordycepin (purity ≥98%) was purchased from the National Institute for the Control of Pharmaceutical and Biological Products (NICPBP) of China, dissolved in DMSO at 0.5 mol/L as stock solution, and stored at −20 °C. During the experiment, stock cordycepin was diluted with culture medium based on the required final concentration. The final concentration of DMSO from the treatment group was less than 0.2% (v/v) versus 0.2% (v/v) from the control group.
Cell culture
Human colorectal cancer cells SW480 and SW620 from the Cancer Institute of Zhejiang University were cultured in Leibovitz L-15 with 10% (v/v) FBS (37 °C, saturated humidity, 5% (v/v) CO 2 ). Cells were collected at the logarithmic growth phase at a density of (0.5-1.0)×10 8 cells/L. Before use in each experiment, cell growth was synchronized by overnight serum starvation.
Cell viability determination
For the determination of cell proliferation, 8×10 3 cells per well were seeded in 96-well plates (100 μl/well). Cordycepin was added after 24 h at final concentrations of 1000, 100, 10, 1, and 0.1 μmol/L versus the control group with 0.2% (v/v) DMSO medium. After 72-h incubation, 20 µl MTS (5 g/L) was added and mixed well, and then the plates were read by a microplate reader (Bio-Rad 450, Hercules, CA, USA) at 0 h (background value) and 3 h at 490 nm. Cell growth inhibition rate was calculated by the following equation: (1−OD exp /OD con )×100%, where OD exp is the experimental group optical density (OD) value and OD con is the control group OD value. For cell counts, 2×10 5 cells per well were seeded in six-well plates (2 ml/well). Cordycepin was added after 24 h at final concentrations of 1000, 100, and 10 μmol/L versus the control group with 0.2% (v/v) DMSO medium. After 24-, 48-, and 72-h treatments, cells were counted after applied by Trypan blue.
Cell cycle analysis and apoptosis detection
A total of 1×10 6 cells were treated for 48 h with 0.25 and 0.50 mmol/L in SW620 cells and 0.65 and 1.30 mmol/L in SW480 cells (1/3 and 2/3 of the half maximal inhibitory concentration (IC 50 ) of appropriate cells). Then cells were washed twice with 0.01 mol/L pH 7.4 PBS, and mixed well with 10 ml 70% (v/v) cold ethanol. After being fixed at 4 °C overnight, cells were centrifuged and the pellets were washed with PBS. Ribonuclease (RNase; final concentration 25 mg/L) was added to the pellets, which were then incubated for 30 min at 37 °C. PI (final concentration at 50 mg/L) was added to the cells, which were incubated at 4 °C in dark for 30 min. Flow cytometry (FCM; BD Co., USA) was used to determine the proportion of dead cells by measuring cell numbers and DNA content at different cell cycle phases.
Annexin V-fluorescein isothiocyanate (FITC) assay
Around 1×10 6 cells were treated with cordycepin, then processed with ethylenediamine tetraacetic acid (EDTA)-free trypsin, and washed twice with PBS. After centrifugation, cells were double-stained with Annexin V-FITC and PI, and then detected at excitation wavelength of 488 nm and emission wavelength of 530 nm. All the analyses were done by FCM (BD Co., USA).
Caspase enzyme activity
A total of 1×10 4 cells were seeded per well on a 96-well plate. After 24-h incubation, different concentrations (1/3 and 2/3 of IC 50 of appropriate cells) of cordycepin were added as treatment group concentrations versus 0.2% (v/v) DMSO medium as the control group. Following the caspase-Glo kit instruction, caspase-3/7, -8, and -9 enzyme activity was measured after another 24-h incubation.
Western blot
Cells were collected, washed with PBS, and lysed at 100 °C for 10 min in buffer. Protein was extracted from SW480 cells after the treatment with cordycepin for 48 h. Western blot was performed according to the Cell Signaling Technology Company's instruction with slight adjustments. Protein expression levels were measured for Bax, Bid, Bim and Puma (Bcl-2 pro-apoptotic members), and also for ERK1/2, p38, and JNK. Blots were reacted at 4 °C overnight with appropriate primary and secondary antibodies (Zhu et al., 2005) .
Statistical analysis
Comparison among groups was performed by using analysis of variance (ANOVA) at a level of 0.05 probabilities with SPSS 16.0. Results are presented as mean±standard deviation (SD).
Results
Cordycepin inhibits the proliferation of colorectal cancer cells
To study the effects of cordycepin on cell proliferation, we used MTS dye assay to analyze the proliferation of SW480 and SW620 cells. The results showed that the proliferation of SW480 (IC 50 is 2 mmol/L) and SW620 (IC 50 is 0.72 mmol/L) cells was significantly inhibited with increasing concentration of cordycepin (Fig. 1a) (P<0.05 or P<0.01) . Additionally, we counted the numbers of SW480 and SW620 cells after the treatment of cordycepin. The results showed that the cell numbers were significantly reduced with cordycepin in dose-and timedependent manners (Fig. 1b) (P<0.01). Our combined results imply that cordycepin inhibited the proliferation of colorectal cancer cells.
Cordycepin arrests cell cycle progression and promotes apoptosis
To study the molecular mechanism by which cordycepin inhibits the proliferation of colorectal cancer cells, we used FCM to analyze the effects of cordycepin on cell cycle progression and apoptosis, and we also measured the caspase enzyme activity of the cells treated with cordycepin. The results showed that the cell cycle progression was significantly inhibited in the G0/G1 phase (Fig. 2a) and apoptosis rates increased significantly after the treatment with cordycepin (Fig. 2b) . Annexin V assay showed early apoptosis induced by cordycepin in both SW480 and SW620 cells (Fig. 2c) . Caspase enzyme activity assay showed that the increase in caspase-3/7 and -9 activity was significant (Fig. 2d ), which agreed with other report (Jen et al., 2009 ). All of these data suggest that cordycepin arrests cell cycle progression and promotes apoptosis. Compared with the control group, the difference was statistically significant (P<0.01).
Cordycepin enhances the protein expression levels of JNK, p38 kinase, and Bcl-2 pro-apoptotic molecules
To study the mechanism by which cordycepin inhibits cell cycle progression and induces cell apoptosis, SW480 cells were used for protein expression analysis. MAPK and Bcl-2 pro-apoptotic members were analyzed as target proteins by Western blot. The results showed that the protein expression levels of JNK and p38 kinase increased significantly after the treatment with cordycepin, while the expression level of ERK1/2 (Fig. 3a) was not affected. The protein expression levels of Bcl-2 pro-apoptotic molecules (Bax, Bid, Bim, and Puma) also changed. Bid and Puma protein expression levels were positively correlated with cordycepin concentration, while the increases of Bid and Puma protein levels were more obvious in lower-dose cordycepin-treated cells (Fig. 3b) . Together, these results imply that cordycepin induced cell apoptosis through activation of JNK and p38 kinase pathways and increases of the expression levels of Bcl-2 pro-apoptotic members such as Bim, Bid, Bax, and Puma.
Discussion
Recent studies have indicated that many of the biological effects of cordycepin are correlated with mammalian target of rapamycin (mTOR) and adenosine monophosphate-activated protein kinase (AMPK) signaling pathways. Cordycepin inhibits mTOR signal transduction and protein synthesis through activation of AMPK (Wong et al., 2010) . It also can induce apoptosis through activation of caspase-9, -3, and -7 (Jen et al., 2009) , change the expression of metabolism-related proteins (Shi et al., 2008) , activate adenosine A3 receptors, reduce the expression of cell-cycle regulating protein cyclin D1 (Yoshikawa et al., 2008) , increase p21WAF1 expression, and activate JNK (Lee et al., 2009) . However, the molecular mechanism underlying cordycepin-induced apoptosis needs to be further understood.
There are three known ways to induce apoptosis: the death receptor pathway, the mitochondrial pathway, and endoplasmic reticulum stress-induced apoptosis. The mitochondrial pathway is the one which has been relatively well studied and understood. Bcl-2 family is the key regulator of the mitochondrial pathway, which includes anti-apoptotic members and pro-apoptotic members (Cory et al., 2003; Niquet and Wasterlain, 2004) . When cells get stimulated by external signals, a protease causes the conformational changes of pro-apoptotic proteins (Bax, Bid, Bim, etc.) which then cause the functionality loss of organelles and the loss of the apoptosis inhibitory activities of anti-apoptotic proteins, leading to the release of various pro-apoptotic factors such as cytochrome c, apoptosis-inducing factors, and Smac. Afterwards, caspase activation breaks important intracellular structural proteins and functional molecules, and ultimately leads to cell apoptosis (Cory et al., 2003; Niquet and Wasterlain, 2004) . Our research shows that, after cordycepin treatment, the protein expression levels of Bax, Bid, Bim, and Puma (Bcl-2 pro-apoptotic members) changed, which suggests that cordycepin might induce apoptosis by increasing the expression levels of Bcl-2 pro-apoptotic members such as Bax, Bid, Bim, and Puma.
The MAPK cell signaling pathway is important for gene regulation since it brings extracellular signals to the nucleus extracellular stimuli (Xia et al., 1995) . The growth factor receptor-mediated MAPK signal transduction pathway was found to be activated at the occurrence of colorectal cancer, and was also found to be closely related to cell proliferation and differentiation; therefore, it could be a potential drug target to prevent and treat cancers (Schwartsmann et al., 2005; Roberts and Der, 2007) . From our study, since cordycepin increased JNK and p38 kinase activity, it indicated that activating JNK and p38 kinase pathways could possibly be a mechanism for cordycepin to induce apoptosis. It has been reported that the activation of MAPK involved a signal transduction pathway that is potentially correlated with Bcl-2 family proteins involved in apoptosis, and JNK and p38 kinase can induce Bax translocation (van Laethem et al., 2004; Gao et al., 2005) ; however, it needs to be further studied whether cordycepin affects the Bc1-2 family to induce apoptosis through MAPKinvolved signaling pathway.
Our research has shown the following conclusions: (1) Cordycepin inhibits the proliferation of colorectal cancer cells SW480 and SW620; (2) Cordycepin inhibits cell cycle progression; thus, the number of G0/G1 phase cells increased; (3) Cordycepin activates JNK and p38 kinase and increases protein expression levels of Bcl-2 pro-apoptotic molecules such as Bax, Bid, Bim, and Puma. This suggests that cordycepin can directly inhibit cell proliferation of SW480 and SW620 cells and induce cell apoptosis. It may activate JNK and p38 kinase MAPK pathways and increase the Bcl-2 family protein expression, then eventually increase the activity of caspase.
